Skip to main content
. 2020 Dec 18;87(7):2807–2817. doi: 10.1111/bcp.14685

FIGURE 1.

FIGURE 1

Flow chart of included PIMs*Number according to the Beers list; additional substances belonging to these classes were on the Dutch market in the study period†1 therapeutic class (NSAIDs) included two different PIMs‡1 PIM included two drug substances (esomeprazole/omeprazole)**PIM criterion also assessed for ≥65 yearsBold in brackets are number of PIMs